alemtuzumab + fludarabine + cyclophosphamide + total body irradiation

This preparative regimen, also known as a conditioning regimen, was developed and evaluated by the M.D. Anderson Cancer Center for patients with peripheral T-cell lymphoma (PTCL) undergoing allogeneic stem cell transplantation. It is a reduced-intensity conditioning (RIC) protocol designed to facilitate donor engraftment and provide anti-lymphoma activity while minimizing the toxicities associated with traditional high-dose conditioning. The regimen consists of alemtuzumab (Campath-1H), a monoclonal antibody that targets the CD52 antigen to provide potent in vivo T-cell depletion; fludarabine, a purine analog that inhibits DNA synthesis; cyclophosphamide, an alkylating agent that causes DNA cross-linking; and low-dose total body irradiation (2 Gy). This combination aims to achieve a balance between sufficient immunosuppression to prevent graft rejection and graft-versus-host disease (GVHD) and the preservation of a graft-versus-lymphoma effect.

Other names

Campath-1H + fludarabine + cyclophosphamide + TBIAlemtuzumab-based reduced intensity conditioningMDACC PTCL Allogeneic Preparative Regimen